Company intelligence / Profile preview

Cortria

Boston, Massachusetts, United Statescortria.com ↗

Ownership: Private
Development stage: Other

Overview

Cortria was a clinical-stage pharmaceutical company developing small molecule therapies targeting cardiovascular and metabolic diseases. Its lead asset, TRIA‑662 (1-methylnicotinamide chloride), completed a Phase 2 study evaluating effects on serum triglycerides and HDL cholesterol. The company focused on safe and well-tolerated medicines for lipid disorders but does not appear to have advanced programs beyond early clinical development or reached commercialization before being acquired.[1][3][5]

Therapeutic areas: CardiovascularMetabolic Disorders
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Cortria.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cortria.

Explore the full profile